PMID- 26297965
OWN - NLM
STAT- MEDLINE
DCOM- 20160818
LR  - 20151027
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 155
DP  - 2015 Nov
TI  - Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining 
      obesity and type 2 diabetes mellitus.
PG  - 49-59
LID - S0163-7258(15)00162-X [pii]
LID - 10.1016/j.pharmthera.2015.08.004 [doi]
AB  - Obesity and type 2 diabetes mellitus (T2DM) are the leading worldwide risk 
      factors for mortality. The inextricably interlinked pathological progression from 
      excessive weight gain, obesity, and hyperglycemia to T2DM, usually commencing 
      from obesity, typically originates from overconsumption of sugar and high-fat 
      diets. Although most patients require medications, T2DM is manageable or even 
      preventable with consumption of low-calorie diet and maintaining body weight. 
      Medicines like insulin, metformin, and thiazolidinediones that improve glycemic 
      control; however, these are associated with weight gain, high blood pressure, and 
      dyslipidemia. These situations warrant the attentive consideration of the role of 
      balanced foods. Recently, we have discovered advantages of a rare sugar, 
      D-allulose, a zero-calorie functional sweetener having strong anti-hyperlipidemic 
      and anti-hyperglycemic effects. Study revealed that after oral administration in 
      rats D-allulose readily entered the blood stream and was eliminated into urine 
      within 24h. Cell culture study showed that D-allulose enters into and leaves the 
      intestinal enterocytes via glucose transporters GLUT5 and GLUT2, respectively. In 
      addition to D-allulose's short-term effects, the characterization of long-term 
      effects has been focused on preventing commencement and progression of T2DM in 
      diabetic rats. Human trials showed that D-allulose attenuates postprandial 
      glucose levels in healthy subjects and in borderline diabetic subjects. The 
      anti-hyperlipidemic effect of D-allulose, combined with its anti-inflammatory 
      actions on adipocytes, is beneficial for the prevention of both obesity and 
      atherosclerosis and is accompanied by improvements in insulin resistance and 
      impaired glucose tolerance. Therefore, this review presents brief discussions 
      focusing on physiological functions and potential benefits of D-allulose on 
      obesity and T2DM.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hossain, Akram
AU  - Hossain A
AD  - Faculty of Medicine, Department of Cell Physiology, Kagawa University, 1750-1, 
      Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
FAU - Yamaguchi, Fuminori
AU  - Yamaguchi F
AD  - Faculty of Medicine, Department of Cell Physiology, Kagawa University, 1750-1, 
      Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
FAU - Matsuo, Tatsuhiro
AU  - Matsuo T
AD  - Faculty of Agriculture, Kagawa University, Ikenobe, Miki-cho, Kita-gun, Kagawa 
      761-0795, Japan.
FAU - Tsukamoto, Ikuko
AU  - Tsukamoto I
AD  - Faculty of Medicine, Department of Pharmacobioinformatics, Kagawa University, 
      1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
FAU - Toyoda, Yukiyasu
AU  - Toyoda Y
AD  - Faculty of Pharmacy, Department of Pathobiochemistry, Meijo University, 
      Tempaku-ku, Nagoya, Aichi, Japan.
FAU - Ogawa, Masahiro
AU  - Ogawa M
AD  - Faculty of Agriculture, Department of Applied Biological Science, Kagawa 
      University, 2393 Ikenobe, Miki-cho, Kagawa-gun 76100795, Japan.
FAU - Nagata, Yasuo
AU  - Nagata Y
AD  - Department of Nutrition, University of Nagasaki, Siebold, 1-1-1 Manabino, 
      Nagayo-cho, Nishisonogi-gun, Nagasaki 859-2195, Japan.
FAU - Tokuda, Masaaki
AU  - Tokuda M
AD  - Faculty of Medicine, Department of Cell Physiology, Kagawa University, 1750-1, 
      Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. Electronic address: 
      tokuda@med.kagawa-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150820
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 23140-52-5 (psicose)
RN  - 30237-26-4 (Fructose)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacokinetics/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Drug Monitoring
MH  - Fructose/pharmacokinetics/*therapeutic use
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/pharmacokinetics/*therapeutic use
MH  - Hypolipidemic Agents/pharmacokinetics/*therapeutic use
MH  - Liver/metabolism
MH  - Obesity/*drug therapy/metabolism
OTO - NOTNLM
OT  - Anti-hyperglycemic
OT  - Anti-obesity
OT  - Functional sweetener
OT  - Rare sugar
OT  - Therapeutic monitoring
OT  - d-Allulose
EDAT- 2015/08/25 06:00
MHDA- 2016/08/19 06:00
CRDT- 2015/08/23 06:00
PHST- 2015/08/03 00:00 [received]
PHST- 2015/08/23 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2016/08/19 06:00 [medline]
AID - S0163-7258(15)00162-X [pii]
AID - 10.1016/j.pharmthera.2015.08.004 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2015 Nov;155:49-59. doi: 10.1016/j.pharmthera.2015.08.004. Epub 
      2015 Aug 20.